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Abstract
Background: A recent human clinical trial of an Alzheimer's disease (AD) vaccine using amyloid
beta (Aβ) 1–42 plus QS-21 adjuvant produced some positive results, but was halted due to
meningoencephalitis in some participants. The development of a vaccine with mutant Aβ peptides
that avoids the use of an adjuvant may result in an effective and safer human vaccine.
Results: All peptides tested showed high antibody responses, were long-lasting, and demonstrated
good memory response. Epitope mapping indicated that peptide mutation did not lead to epitope
switching. Mutant peptides induced different inflammation responses as evidenced by cytokine
profiles. Ig isotyping indicated that adjuvant-free vaccination with peptides drove an adequate Th2
response. All anti-sera from vaccinated mice cross-reacted with human Aβ in APP/PS1 transgenic
mouse brain tissue.
Conclusion: Our study demonstrated that an adjuvant-free vaccine with different Aβ peptides can
be an effective and safe vaccination approach against AD. This study represents the first report of
adjuvant-free vaccines utilizing Aβ peptides carrying diverse mutations in the T-cell epitope. These
largely positive results provide encouragement for the future of the development of human
vaccinations for AD.
Background
Currently, more than five million people in the United
States suffer from Alzheimer's disease (AD), and given our
aging population, this prevalence is expected to continue
to rise [1]. Neuropathologic hallmarks in AD include the
formation of toxic amyloid β (Aβ), its aggregation into
globular oligomers (plaques) in the brain, and the subse-
quent formation of a neurotoxic protein leading to cogni-
tive and behavioral deficits and neurodegeneration [2].
One reasonable approach to this future public health cri-
sis is to decrease the incidence and possibly prevalence of
AD through the development and administration of a
human vaccination that prevents, slows, or removes this
AD pathology in human brains.
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The first attempt at developing such a vaccine was docu-
mented in 1999, when Schenk et al. reported that Aβ1–42,
when used as an active vaccine, can effectively remove Aβ
plaques in AD transgenic mouse brains [3]. Another mile-
stone vaccine study published in 2000 showed that the
use of Aβ1–42 plus adjuvant as an active vaccine in the AD
transgenic mouse model not only induced an effective
remission of Aβ plaques in the brain [4], but also led to
cognitive and behavioral improvements [5]. In other
mouse model studies, passive immunotherapy with anti-
Aβ antibodies produced similar results [6,7]. Further,
Yamamoto et al. demonstrated that antibodies to Aβ1–42
may effectively inhibit the deposition of Aβ in the brain
[8]. Weiner et al. also reported plaque-lowering in PDAPP
transgenic mice after an intranasal inoculation of Aβ with-
out adjuvant [9].
Mutated peptides have been shown to have different phe-
notypes. Mutations in the APP gene and the resulting
mutant Aβ peptides are highly associated with autosomal
dominant AD. The Dutch and Flemish mutations are
known to cause patterns of aggregation that strongly differ
from those with wild type (Wt) Aβ peptide [10,11]. Fur-
ther, the Dutch and Flemish mutations have different phe-
notypes [12]. While both the Dutch and Flemish
mutations cause hemorrhage and amyloidosis in patients,
only the Flemish mutation causes AD [13,14].
In addition, it is important to consider the possibility that
vaccination with Aβ may induce an unwanted inflamma-
tory response. Popovic et al. report that the presence of
antigen-presenting HLA-DR-positive and other immu-
noregulatory cells together with abnormal levels of
inflammatory cytokines and acute phase reactants are
consistently detected in tissue of AD neuropathology [15].
It has been theorized that AD-related inflammation could
be a form of autoimmunity that potentially marks a more
specific and progressive state of the disease [16]. Vaccina-
tion with an Aβ peptide, therefore, runs the risk of exacer-
bating this inflammation. And because vaccine adjuvants
themselves can cause varying levels of inflammation [17],
the effect of the adjuvant is important to consider in the
development of an AD vaccine.
The increased success with vaccinations using Aβ peptides
in mouse models of AD encouraged a human clinical trial.
The study was a randomized, multi-centered, placebo-
controlled, double-blind trial using Wt Aβ peptide
AN1792 as a vaccine in combination with the adjuvant
QS-21 combined with polysorbate-80 [18,19]. The trial
included patients aged 50 to 85 years of age with probable
AD as determined by the Mini-Mental State Examination
(MMSE) [20]. Unfortunately, meningoencephalitis
occurred in 6% of the 298 participants, forcing this Phase
II trial to be suspended by the United States Food and
Drug Administration. However, in a follow-up study of
the vaccinated patients, some benefits were seen, includ-
ing reduced AD-like pathology on autopsy [21] and
improved cognition [22]. While this study suggests that a
vaccination with an Aβ peptide may be helpful in
humans, more work must be done to develop one that
does not produce such serious side effects.
The cause of the adverse events in the AN1792 trial has
not been identified, and further analysis is required to
determine the mechanism of neuroinflammation and the
associated meningoencephalitis. As part of the analysis, it
is necessary to consider that the inflammatory response
might actually have been triggered, at least in part, by the
adjuvant, and not the antigen [17,23]. It has been pro-
posed that the polysorbate-80 that was added to the QS-
21 adjuvant to keep it from precipitating out may have
contributed to the meningoencephalitis in the AN1792
trial [18]. In fact, other studies have shown that adjuvants
themselves induce significant pro-inflammatory cytokine
expression in vivo including up-regulation of TNF-α, IFN-
γ, and IL-4, even without being coupled to an antigen
[23]. Immune modulation may also be affected by adju-
vant administration, and this must be taken into account
when selecting a particular adjuvant. Importantly, this
modulation may result in the production of different anti-
body subclasses [24]. These negative properties associated
with adjuvants suggest that an adjuvant-free vaccine for
AD would be an attractive prospect.
Historically, the use of an adjuvant in vaccination was
necessary to prime the immune system. However, our
research group recently reported that mutations in the
Aβ1–42 peptide can change the antigenicity of the peptide
[10]. This was further supported by a study by Arendash et
al. which demonstrated that adapted transfusion of Aβ-
peptide-specific T-cells into AD transgenic mice can
reverse cognitive impairment, suggesting that T-cell acti-
vation may be necessary for Aβ clearance [25]. The Aβ
peptide itself contains two strong B-cell epitopes, as well
as a strong T-cell epitope [10]. Previous studies suggested
that adjuvant-free vaccination might help identifying
pathways of autoimmunity [26]. These findings suggest
that the Aβ peptide itself may be able to serve as its own
adjuvant.
One of the participants in the AN1792 trial was found to
have multiple cortical hemorrhages upon autopsy [27].
Indeed, mouse model studies have suggested that hemor-
rhage may be an adverse event of Aβ vaccination that must
be considered in the development of human Aβ vaccines
[28-30]. The mechanism behind hemorrhage post-Aβ
clearance has been proposed to be due to weakening of
the vessel walls [28]. We believe that a vaccine that causes
Aβ clearance in the brains of older human patients canBMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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still be developed; however, the clearance should happen
at a slow, steady rate to allow the vessel walls to acclimate
to the removal of the plaque. This suggests that an appro-
priate vaccine should not induce a strong, quick immune
response. Rather, a good vaccine for the purpose of Aβ
plaque removal would demonstrate a slow increase in
antibody that held at stable levels for a long duration in
which memory response could be demonstrated. This is
in contrast to the goal of prophylactic vaccines, which is
to induce a quick and strong immune response in the vac-
cine.
The current scientific goal is to build upon our under-
standing of the results of the AN1792 trial to find a safer
and more effective vaccine candidate. The aim of this
study is to test adjuvant-free vaccines using Aβ peptides,
both Wt and those with mutations in the T-cell epitope,
and evaluate their efficacy and safety. Here, we report the
successful vaccination of BALB/c mice with several adju-
vant-free mutated Aβ peptides.
Results
Antibody response
Mutated and Wt Aβ1–42 peptide vaccinations induced
clear antibody responses after 2 inoculations (data not
shown) and high antibody level after 3 inoculations,
while no antibody could be detected in the control group
(Figure 1). There was a high antibody response 10 days
after the third vaccination for all peptide vaccine groups at
1:1024 dilutions, and antibody titers rose to greater than
1:4096 in all peptide vaccine groups (data not shown).
There were no differences in peptide recognition among
various anti-sera and peptides, with the exception of Wt
(PWT) and P24M (novel mutation), which were higher
regardless of coating antigen (Figure 2). Antibody was
long-lasting, showing duration of up to 4 months (Figure
3). Memory response was also apparent when comparing
antibody levels before and after boosting (Figure 4).
In summary, all peptides used in this study induced good
antibody responses. However, PFM (Flemish mutation),
PFDM (Dutch and Flemish mutation) and P22W (novel
mutation) had better antibody duration responses.
Epitope Mapping
All antibodies induced by the different peptides injected
demonstrated binding to Wt Aβ1–16 and 1–35 (Figure 5).
Figure 6 shows non-adjuvant epitope mapping in blue
(data from the current study) compared to adjuvant vac-
cine epitope mapping in purple from a previously pub-
lished study [10]. In this previous study, MPL+TDM
(Sigma Aldrich, MO) was used as an adjuvant because
Freud was prohibited for use in vaccine studies in mice,
and MPL+TDM is water soluble (thus preventing aging of
the peptide), avoids emulsification of the peptide, and
preserves the antigen [31]. MPL has been demonstrated to
drive a Th1 response in mice [32,33] and performed sim-
ilarly in our earlier study as in other vaccine studies using
this adjuvant [34]. It is apparent there is no difference in
epitope between the adjuvant and non-adjuvant. Toellner
et al has reported a study that cautions that mutant pep-
Cross-reaction analysis of binding to various Aβ peptides Figure 2
Cross-reaction analysis of binding to various Aβ pep-
tides. Note: ELISA result for antibody detection at 1:1024 
dilutions using different Aβ1–42 peptides as capture antigens 
at 10 µg/ml (50 µl/well). There are good peptide cross recog-
nitions (n = 4 in each group). PWT = Wild type Aβ1–42, 
PFM = Aβ1–42 with Flemish mutation, PDM = Aβ1–42 with 
Dutch mutation, PFDM = Aβ1–42 with Flemish and Dutch 
mutation, P22W = Aβ1–42 with novel mutation at 22, P24M 
= Aβ1–42 with novel mutation at 24 amino acid.
Antibody detection after 3 inoculations with different Aβ  peptides Figure 1
Antibody detection after 3 inoculations with different 
Aβ peptides. Note: ELISA result for antibody detection at 
1:1024 dilutions using Aβ1–42 wild type as capture antigen at 
10 µg/ml (50 µl/well) (n = 4 in each group). Ctr = Control, 
PWT = Wild type Aβ1–42, PFM = Aβ1–42 with Flemish 
mutation, PDM = Aβ1–42 with Dutch mutation, PFDM = 
Aβ1–42 with Flemish and Dutch mutation, P22W = Aβ1–42 
with novel mutation at 22, P24M = Aβ1–42 with novel muta-
tion at 24 amino acid.BMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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tides may be subject to epitope switching [35]. Our results
indicate that there was no epitope switching among muta-
tions, and additionally, there were no differences in
epitope when compared to the adjuvant vaccine.
Cytokine Expression, T-cell Response and IgG Isotyping
Several peptides induced low levels of IL-6, TNF-α, IL-2,
and IL-5 (Figures 7a and 7b). All peptides except P22W
produced an IgG1/IgG2a ratio that was either higher or no
different post-vaccination than pre immunization. This
indicates a high Th2 response (see Figure 8). Also per Fig-
ure 8, PDM, PFDM and P24M demonstrated a Th2 type
antibody response.
Comparison of epitope mapping of Aβ peptide with and  without adjuvant using various Aβ fragments Figure 6
Comparison of epitope mapping of Aβ peptide with 
and without adjuvant using various Aβ fragments. 
Note: ELISA results for epitope mapping using various Aβ 
peptide fragments as capture antigens at 20 µg/ml (50 µl/
well) and plasma diluted at 1:1024 dilutions. Blue bar repre-
sents non-adjuvant vaccine (current study), while purple bar 
represents results from a previous adjuvant study [10]. PWT 
= Wild type Aβ1–42, PWT+MPL = Wild type Aβ1–42 mixed 
with monophosphoryl lipid A (MPL) as an adjuvant.
Immune memory response following booster injection Figure 4
Immune memory response following booster injec-
tion. Note: ELISA results for antibody detection using Aβ1–
16 as capture antigen at 10 µg/ml (50 µl/well) and plasma 
diluted at 1:3200 dilutions. Blue bar shows antibody detec-
tion 6 months after third inoculation and just prior to boost, 
and red bar shows 10 days after boost. PDM = Aβ1–42 with 
Dutch mutation, P24M = Aβ1–42 with novel mutation at 24 
amino acid.
Antibody duration after 3 inoculations at 1, 2, 3, and 4  months Figure 3
Antibody duration after 3 inoculations at 1, 2, 3, and 
4 months. Note: ELISA results for antibody detection using 
Aβ1–16 as capture antigen at 20 µg/ml (50 µl/well), plasma 
were diluted at 1:2048 dilutions. There is no statistically sig-
nificant reduction four months after vaccination. PWT = 
Wild type Aβ1–42, PFM = Aβ1–42 with Flemish mutation, 
PDM = Aβ1–42 with Dutch mutation, PFDM = Aβ1–42 with 
Flemish and Dutch mutation, P22W = Aβ1–42 with novel 
mutation at 22, P24M = Aβ1–42 with novel mutation at 24 
amino acid.
Epitope mapping of anti-sera using various Aβ fragments Figure 5
Epitope mapping of anti-sera using various Aβ frag-
ments. Note: ELISA results for epitope mapping using vari-
ous Aβ peptide fragments as capture antigens at 20 µg/ml (50 
µl/well) and plasma were diluted at 1:1024 dilutions. PWT = 
Wild type Aβ1–42, PFM = Aβ1–42 with Flemish mutation, 
PDM = Aβ1–42 with Dutch mutation, PFDM = Aβ1–42 with 
Flemish and Dutch mutation, P22W = Aβ1–42 with novel 
mutation at 22, P24M = Aβ1–42 with novel mutation at 24 
amino acid.BMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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We also compared Wt and Dutch mutation IgG1/IgG2a
ratio with data from a previous study [10] to compare Th1
or Th2 response to peptides administered with adjuvant.
As shown in Figure 9, non-adjuvant vaccine induced a
higher Th2 response compared to adjuvant vaccine in
both Wt and Dutch mutation peptides.
In conclusion, some of the non-adjuvant peptide vaccines
were directed towards a Th2 response (Figure 9), and also
showed a peptide-specific response (Figure 8). PDM,
PFDM and P22W showed lower pro-inflammation
response (Figures 7a and 7b).
IgG1/IgG2a ratio pre- and post-vaccination with various Aβ  peptides Figure 8
IgG1/IgG2a ratio pre- and post-vaccination with vari-
ous Aβ peptides. Note: As measured by Beadlyte® Mouse 
Immunoglobulin Isotyping Kit; Wild type Aβ1-42 = Wild type 
Aβ1–42, Aβ1-42 with Flemish mutation = Aβ1–42 with 
Flemish mutation, Aβ1-42 with Dutch mutation = Aβ1–42 
with Dutch mutation, Aβ1-42 with Flemish and Dutch muta-
tion = Aβ1–42 with Flemish and Dutch mutation, Aβ1-42 
with novel mutation at 22 = Aβ1–42 with novel mutation at 
22, Aβ1-42 with novel mutation at 24 amino acid = Aβ1–42 
with novel mutation at 24 amino acid.
Cytokine response to vaccination with various Aβ peptides:  IL-6, TNF-α, IL-2, and IL-5 Figure 7
Cytokine response to vaccination with various Aβ 
peptides: IL-6, TNF-α, IL-2, and IL-5. Note: Ratio of 
post- to pre-vaccination cytokine levels are shown. Ctr = 
Control, PWT = Wild type Aβ1–42, PFM = Aβ1–42 with 
Flemish mutation, PDM = Aβ1–42 with Dutch mutation, 
PFDM = Aβ1–42 with Flemish and Dutch mutation, P22W = 
Aβ1–42 with novel mutation at 22, P24M = Aβ1–42 with 
novel mutation at 24 amino acid. Top figure (7a) shows 
results for IL-6 and TNF-α and bottom figure (7b) shows 
results for IL-2 and IL-5.
Comparison of IgG1/IgG2a ratio post-vaccination of wild  type and Dutch mutation Aβ peptides with and without adju- vant Figure 9
Comparison of IgG1/IgG2a ratio post-vaccination of 
wild type and Dutch mutation Aβ peptides with and 
without adjuvant. Note: As measured by Beadlyte® Mouse 
Immunoglobulin Isotyping Kit; PWT = Wild type Aβ1–42, 
PDM = Aβ1–42 with Dutch mutation. Striped bars report 
results from current study; checkered bars report results 
from a previous study [10].BMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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Anti-sera cross-reactivity
Figure 10 shows the results of immunostaining of cortex
tissue from a human APP/PS1 transgenic mouse. Anti-sera
from BALB/c mice in each vaccination group was added to
the tissue; each panel represents a different vaccination
group. Per the figure, binding to plaques was demon-
strated for each vaccination group.
Discussion
We found several adjuvant-free vaccine candidates that
produced results suggesting both efficacy and safety. Sev-
eral candidates demonstrated a good antibody response
that lasted at least 4 months (Figure 3), and showed good
memory response after boost (Figure 4). These findings
are consistent with the AN1792 follow-up findings by
Hock et al. in which sustained increases in serum antibod-
ies against Aβ were demonstrated [22]. Epitope mapping
was shown to be no different between our non-adjuvant
and other adjuvant-containing vaccines, and Th2
response was observed among some of the non-adjuvant
peptides tested. These results are encouraging, suggesting
Cross reaction of antisera from BALB/c mice vaccinated with different adjuvant-free peptide vaccines to cortex brain section of  a 14-month-old APP/PS1 transgenic mouse Figure 10
Cross reaction of antisera from BALB/c mice vaccinated with different adjuvant-free peptide vaccines to cor-
tex brain section of a 14-month-old APP/PS1 transgenic mouse. Each panel is described below: a. Immunostaining 
with 6E10 antibody (Signet; Philadelphia, PA). b. Immunostaining with antisera from BALB/c mice vaccinated with PFM peptide. 
c. Immunostaining with antisera from BALB/c mice vaccinated with P22W peptide. d. Immunostaining with antisera from BALB/
c mice vaccinated with P24M peptide. e. Immunostaining with antisera from BALB/c mice vaccinated with PFDM peptide. f. 
Immunostaining with antisera from BALB/c mice vaccinated with PDM peptide. g. Immunostaining with antisera from BALB/c 
mice vaccinated with PWT peptide
Table 1: Peptides sequences.
Peptide name Sequence of each peptide
Aβ1–42 Wild type (PWT) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Aβ1–42 with Flemish mutation (PFM) DAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGVVIA
Aβ1–42 with Dutch mutation (PDM) DAEFRHDSGYEVHHQKLVFFAQDVGSNKGAIIGLMVGGVVIA
Aβ1–42 with Flemish and Dutch mutation (PFDM)* DAEFRHDSGYEVHHQKLVFFGQDVGSNKGAIIGLMVGGVVIA
Aβ1–42 with novel mutation (P24M)** DAEFRHDSGYEVHHQKLVFFAEDGGSNKGAIIGLMVGGVVIA
Aβ1–42 with novel mutation (P22W)*** DAEFRHDSGYEVHHQKLVFFAMDVGSNKGAIIGLMVGGVVIA
Note: Mutations or changes are underlined and bold, *medium affinity, **high affinity, ***low affinity.BMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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we have identified peptides that may be effective for
human vaccination.
In terms of safety, in our study of non-adjuvant peptide
vaccines, inflammation levels varied minimally among
the groups of mice vaccinated with mutated Aβ peptides,
and those levels differed from controls as well as levels in
mice vaccinated with Wt peptide. The cytokine profiles for
mutated peptide vaccinated mice indicated a peptide-spe-
cific response with elevated Th1 (TNF-α, IL-2) and Th2
(IL-5 and IL-6) associated cytokines. Cytokine profiles in
our study showed peptide-specific differences with respect
to markers of pro-inflammation, such as TNF-α and IL-6
(Figure 7a). Some mutated peptides induced an anti-Aβ
antibody IgG1 response (PWT and P22W), while others
induced an IgG2a response, such as PDM, PFDM and
P24M (Figure 8); this can be compared to PWT and PDM
with adjuvant vaccine, which induced a significant Th1
response (Figure 9). In addition, pro-inflammatory
cytokine levels were not correlated with antibody titers
(Figures 1 and 2). Given that the Th2 response to the adju-
vant-free vaccines in our study was higher when compared
to adjuvant vaccine response, and that there was no evi-
dence of these peptides inducing unwanted inflamma-
tion, avoiding the use of an adjuvant may be beneficial. If
a poor Th1 response was part of the reason for the menin-
goencephalitis in the AN1792 trial, using a non-adjuvant
vaccine with one of the candidate peptides used in this
study would be a reasonable approach.
One of the major concerns regarding vaccination with
mutated peptides is epitope switching [35-37]. Our results
show that all peptides in the presence or absence of adju-
vant map to the same epitope (Figure 6), suggesting that
this was not a concern in our study.
Our study has several strengths. An important strength of
our study is that we tested several peptides and identified
several candidates for further study. T-cell response was
indeed variable across the peptides tested, but our results
offer the choice of peptides for further study based upon
these data. For example, PDM and PFDM demonstrated a
low inflammatory response (Figures 7a and 7b), but a
high Th2 response (Figure 8). We also demonstrated that,
with these vaccinations, an adjuvant is not necessary to
achieve the desired responses.
On the other hand, our study also has limitations. Like the
AN1792 vaccination, the peptides used in our study con-
tained the entire T-cell epitope. Using peptides that
include only part of the T-cell epitope might improve the
desired inflammatory response to the vaccine, and should
be a subject of future study. In addition, although we
measured cytokine expression and conducted antibody
isotyping, we did not actually measure T-cell responses.
Results from our previous study suggested that the T-cell
epitope is related to haplotype [10], so we will conduct T-
cell epitope mapping when we conduct this study in a
transgenic mouse model. Finally, our study was done only
in BALB/c mice, so the results need to be confirmed by
conducting a similar study in APP transgenic mice. Since
there is a high level endogenous Aβ produced in trans-
genic mice, immune response may be different compared
to BALB/c mice [38]. It is also unclear how the results may
translate to other animals and to humans.
Conclusion
Our study demonstrated that an adjuvant-free vaccine
with different Aβ peptides can be an effective and safe vac-
cination approach against AD. Our adjuvant-free vaccines
induced a good antibody response without stimulating an
unwanted inflammation reaction. Furthermore, muta-
tions in the T-cell epitope did not affect the B-cell epitope,
but generated different levels of inflammation response.
Our results provide several mutant Aβ peptides as viable
candidates for further study of adjuvant-free vaccines. Fur-
ther studies in which the entire T-cell epitope is not con-
tained in the Aβ peptide are also warranted, as this may
further address inflammatory reactions.
This study represents the first report of adjuvant-free vac-
cines utilizing Aβ peptides carrying diverse mutations in
the T-cell epitope. These largely positive results provide
encouragement for the future of the development of
human vaccinations for AD.
Methods
Animals
Ten-week-old female BALB/c mice were obtained for the
study from Jackson Laboratories (Bar Harbor, ME). It is
recognized that BALB/c mice "demonstrate Th2-biased
immune responses" [39]. Because we were testing novel
mutant peptides, and because AD itself is associated with
a Th1 response, we felt BALB/c mice were the most appro-
priate choice for this study.
One 14-month-old APP/PS1 transgenic (tg) mouse was
used for immunostaining studies. The mouse was pro-
vided by the Florida Alzheimer's Disease Research Center
Mouse Behavior and Neuropathology Core.
The mice were housed in Varian standard cages including
amber igloos. Prior to initiation of the study, approval was
obtained from the Institutional Animal Care and Use
Committee (IACUC) at our institution.
Vaccination
Aβ1–42 peptides were obtained from Synpep (Dublin,
CA) based on human Aβ1–42 peptide sequence. Peptides
for vaccination were reconstituted to 10 mg/ml in DMSOBMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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and further diluted to 2 mg/ml with phosphate buffered
saline. Aβ peptide is highly hydrophobic, so we used
DMSO (per manufacturer's instructions) to reconstitute it
and keep it at a high concentration. We acknowledge that
DMSO has been used in previously tested vaccines and
may induce an immune response [40-43]. However, we
conducted a pilot study in which we injected a human
immunodeficiency virus (HIV) peptide into BALB/c mice
using the same amount of DMSO as an adjuvant in one
group, and HIV peptide using MPL+TDM (Sigma Aldrich;
St. Louis, MO) as an adjuvant in another group. The pep-
tide plus DMSO did not induce an antibody response, but
peptide plus MPL did (data not shown). Therefore, we
concluded that DMSO would not induce an antibody
response against the injected peptide in this study. For this
reason, although DMSO has been used in other studies as
an adjuvant, we do not consider it an adjuvant in this
study.
Aβ1–42 peptides were not aged prior to injection. This is
because we believe that aggregated Aβ peptide will inhibit
epitope presentation compared to unaggregated peptide.
In addition, Aβ aggregation in the brain as part of AD is
considered a main cause of inflammation seen in these
patients [44], so avoiding the injection of aggregated Aβ
should reduce the risk of inducing unwanted inflamma-
tion.
Twenty-eight (28) mice were divided into 7 groups, each
containing 4 mice. Six (6) different mutated Aβ1–42 pep-
tides were used in the study. Each group received one of
the 6 peptides, with the final group receiving PBS contain-
ing 10% DMSO to serve as a control group.
An initial subcutaneous vaccination was given at 100 µg
peptide in 100 µl when mice were 14 weeks old. The next
booster vaccination was given 2 weeks later, at 100 µg
peptide (100 µl). Finally, 2 weeks later, a third inoculation
was carried out with 50 µg peptide in 100 µl.
Peptide selection
We had decided a priori to include Aβ1–42 Wt, Aβ1–42
with Dutch mutation, and Aβ1–42 with Flemish mutation
in the study to build upon already published reports
[11,12], as well as a control group. Therefore, we were left
with enough resources to test 3 additional peptides.
To select these 3 peptides, we took Wt Aβ1–42 and created
100 candidate peptides from introducing mutations at
various places. Next, we conducted HLA peptide motif
analysis [45] to assist us in choosing peptides. We decided
to choose 1 peptide with high affinity, 1 with medium
affinity, and 1 with low affinity. "High affinity" was con-
sidered as having an HLA affinity score >4,000, "medium"
was designated as having a score equal to Wt score (which
was between 400 and 1,000), and "low" was considered
<100. The sequences for the peptides we chose are given
in Table 1.
Blood Tissue and Plasma Collection Procedures
Ten days after each injection, mice were bled by sub-
mandibular phlebotomy using an 18-gauge needle and
collected into an EDTA inclusive tube. Plasma was sepa-
rated by centrifugation 1500 g for 20 minutes with Stat-
Sampler from StatSpin (MA). Isolated plasma was frozen
at -80°C.
Antibody Titer Determination
Anti-Aβ antibody (6E10) was purchased from Signet Lab-
oratories (Dedham, MA) and used as a positive control.
Antibody levels post-vaccination were assayed via ELISA
using Aβ1–42 peptide as the binding antigen. Briefly, 96
well plates were coated with 50 µl Aβ1–42 in cap-binding
complex (CBC) buffer (50 mM sodium carbonate, pH
9.6) at 10 µg/ml. A CBC plate is a plate coated with CBC
buffer used as a background detection method in order to
correct the non-specific binding of sera to the micro plate.
A CBC plate was set up as a binding background. Then,
both Aβ and CBC coated plates were incubated overnight
at 4°C. After 5 washes, plates were subjected to a blocking
step with 180 µl blocking buffer (1XPBS containing 1.5%
BSA), and incubated for 1 hour at 37°C. Plates were then
washed 5 times with wash buffer, and samples diluted
with blocking buffer and added to both Aβ and CBC
plates at two-fold serial dilutions starting at 1:100. Sam-
ples were incubated at 37°C for 1 hour, then subjected to
12 washes with wash buffer. HRP-conjugated anti-mouse
IgG (Sigma Aldrich) were loaded into each well at a
1:5000 dilution, incubated for 1 hour at 37°C, then
washed 12 times. TMB peroxidase substrate was dissolved
in PCB buffer, and 100 µl were added to each well. Color-
imetric reactions were stopped with 25 µl 2N H2SO4.
Plates were read at 450 nm/630 nm, and samples with
readings 3 times higher than controls were considered
positive. The highest dilution was used as the endpoint
titer.
Epitope mapping
Different Aβ peptide fragments (Aβ1–16, 12–28, and 29–
42) as well as Aβ1–35 at 20 µg/ml were used to coat a 96-
well plate with 50 µl per well. The plate was blocked with
180 µl blocking buffer and blocked for 1 hour at 37°C,
then washed 5 times with wash buffer. Pre- and post-
immune sera were loaded with serials dilutions. ELISA
was conducted using the same protocol described above
for the titer assay.
Cytokine expression detection
The cytokine expression profiles were detected using the
Bio-Rad Inc. Bio-Plex kits (Bio-Rad, catalogue #BMC Neuroscience 2008, 9:25 http://www.biomedcentral.com/1471-2202/9/25
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171F11181). Samples and standards were prepared using
company protocols with the initial concentration of
standards ranging from 32,000 pg/ml to 1.95 pg/ml.
Plasma samples were prepared for analysis by diluting 1
volume of the serum sample with 3 volumes of the Bio-
Plex mouse sample diluent. Wells on the 96-well filter
plate were pre-wetted with 100 µl of Bio-Plex assay buffer.
The buffer was removed by vacuum filtration. The multi-
plex bead-working solution was vortexed for 15 to 20 sec
at medium speed, and 50 µl was pipetted into each well.
One-hundred (100) µl of Bio-Plex wash buffer was also
pipetted into each well, and then removed by vacuum fil-
tration. Fifty (50) µl of diluted standard was added to
wells in the first two columns, and sample was added the
remaining wells. The plate was covered with aluminum
foil and placed onto a microplate shaker. Samples were
incubated for 30 minutes at room temperature.
At the end of the incubation, the reagents were removed
by vacuum filtration, and plates were washed 3 times. The
Bio-Plex detection antibody working solution was vor-
texed gently and 25 µl was added to each well. The entire
plate was then covered with a new sheet of sealing tape,
followed by a sheet of foil. The plate was then incubated
at room temperature with shaking for 30 minutes. After-
ward, the sealing tape was removed and the liquid
extracted by vacuum filtration. This was followed by 3
washes, with blotting in between each wash.
One-x (1x) streptavidin-PE was vigorously vortexed, and
50 µl pipetted into each well. The plate was again covered
with sealing tape and foil, then incubated at room temper-
ature with shaking for 10 minutes. After incubation, the
sealing tape was again removed, the liquid extracted by
vacuum filtration, and 3 wash steps with blotting in
between were performed. The beads were then re-sus-
pended in each well with 125 µl of Bio-Plex assay buffer.
The plate was again covered with a new sheet of sealing
tape and incubated at room temperature with shaking for
30 seconds.
Finally, the plates were read. Because of the naturally-
occurring variability of cytokine levels, optical density
readings for each cytokine were normalized to a 0–1 scale
that was used to compare animal groups.
IgG isotyping
To further confirm the inflammation and the contribu-
tion of cytokines to Ig subclass switching modulation, we
detected Ig isotyping by using the Beadlyte® Mouse Immu-
noglobulin Isotyping Kit by Upstate Cell Signaling Solu-
tions (Temecula, CA), and following manufacturer's
instructions. Total Ig isotyping was assayed instead of
anti-Aβ-specific antibody because any Ig difference in the
same mouse is due to the antigen stimulation. In addi-
tion, this method allows the monitoring of overall Ig
change pre- and post-vaccination. This method produces
an IgG1/IgG2a ratio and this ratio helps to differentiate
Th1 or Th2 responses in vaccinated mice. Because IgG1 is
driven by IL-4 (Th2), and IgG2a is driven by IFN-γ (Th1)
[35], an increase in post-vaccination ratio indicates a Th2
response, and a decrease in post-vaccination ratio indi-
cates a Th1 response.
Immunostaining
To evaluate antibodies generated from BALB/c mice,
cross-reaction to human Aβ was evaluated in tg mouse
brain tissue. Tg mice were euthanized with an overdose of
anesthesia, brain blood was removed by intracardial per-
fusion, and brain tissue was harvested as per established
protocol [46]. Immunostaining assay was completed as
previously described by Nilsson et al. [46].
Statistical analysis
All data were analyzed using analysis of variance
(ANOVA). After interpreting the results of the ANOVA
models, post-hoc differences between groups (pair-by-
pair differences) were assessed using Fisher's Least Signif-
icant Differences (LSD) test.
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